Optimizing the Design of Clinical Trials to Evaluate the Efficacy of Function-Promoting Therapies

Keyphrases

• Chronic Disease 100%
• National Institutes of Health 100%
• Muscle Mass 100%
• Age-related Illnesses 100%
• Clinical Trial Design 100%
• Pharmaceutical Industry 100%
• Functional Training 100%
• Older Adults 50%
• Adverse Outcomes 50%
• Acute Disease 50%
• Professional Societies 50%
• Physical Function 50%
• Hospitalization 50%
• Behavioral Strategy 50%
• Drug-induced 50%
• Frailty 50%
• Sarcopenia 50%
• Pharmacological Agents 50%
• Functional Limitations 50%
• Geriatrician 50%
• Cancer Cachexia 50%
• Performance-based 50%
• Health Administration 50%
• Mobility Impairment 50%
• Functional Improvement 50%
• Cognitive Strategies 50%
• Physical Limitations 50%
• Mass Gain 50%
• Life Functioning 50%
• Early Phase Clinical Trials 50%
• Trial Design 50%
• Fall-related Injuries 50%
• Patient-reported Measures 50%
• Functional Tasks 50%
• Health Food 50%
• Balance Task 50%
• Stability Strength 50%
• Regulatory Guidance 50%
• Pharmaceutical Professionals 50%
• Balance Stability 50%

Medicine and Dentistry

• Clinical Trial 100%
• Chronic Disease 100%
• Functional Training 100%
• Biological Marker 50%
• Frailty 50%
• Sarcopenia 50%
• Geriatrician 50%
• Cachexia 50%
• Adverse Outcome 50%
• Functional Limitation 50%
• Acute Disease 50%
• Walking Difficulty 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Trial 100%
• Chronic Disease 100%
• Biological Marker 50%
• Adverse Outcome 50%
• Acute Disease 50%
• Cachexia 50%
• Sarcopenia 50%
• Frailty 50%
• Walking Difficulty 50%